US Stock MarketDetailed Quotes

KPTI Karyopharm Therapeutics

Watchlist
  • 0.617
  • +0.007+1.13%
Close Feb 14 16:00 ET
  • 0.620
  • +0.003+0.55%
Post 19:54 ET
77.81MMarket Cap-0.59P/E (TTM)

Karyopharm Therapeutics Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

Karyopharm Therapeutics Q4 2024 Estimates Date

Currency：USDFeb 19, 2025

Estimate YoY
Revenue
35.67M
+5.71%
EPS
-0.27
+25.01%
Analyst Rating
Strong Buy

Feb 17, 2025

Karyopharm Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 3 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 37.826M--
Feb 19, 20252024/Q4-- / 35.674M--
Nov 5, 20242024/Q338.783M / 37.924M--
Aug 6, 20242024/Q242.786M / 36.213M--
May 8, 20242024/Q133.126M / 34.473M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 37.826M--
Feb 19, 20252024/Q4-- / 35.674M--
Nov 5, 20242024/Q338.783M / 37.924M--
Aug 6, 20242024/Q242.786M / 36.213M--
May 8, 20242024/Q133.126M / 34.473M--

Unlock Free Earnings Estimates

Karyopharm Therapeutics Earnings Reports

  • Karyopharm Therapeutics | 10-Q: Q3 2024 Earnings Report

    Nov 5, 2024 07:51 ET

  • Karyopharm Therapeutics | 10-Q: Q2 2024 Earnings Report

    Aug 6, 2024 07:43 ET

  • Karyopharm Therapeutics | 10-Q: Q1 2024 Earnings Report

    May 8, 2024 17:18 ET

  • Karyopharm Therapeutics | 10-K: FY2023 Annual Report

    Feb 29, 2024 07:48 ET

    • Read more

    Trending Stocks
    Best Growth Stocks Best Growth Stocks

    Spot stocks with huge growth potential and solid financial standing. Spot stocks with huge growth potential and solid financial standing.

    Symbol Mini Chart % Chg
    DOMINOS PIZZA ENTERPRISES LIMITED UNSP ADR EACH REPR 0.5 ORD SHS
    DMZPY
    +17.56%
    DexCom
    DXCM
    +5.92%
    Hutchmed (China)
    HCM
    +4.39%
    New Fortress Energy
    NFE
    +2.70%
    Enerpac Tool
    EPAC
    +1.85%

    Unlock the Full List

    Analysis

    Analyst Rating

    Updated: Feb 17, 2025

    Strong Buy

    • Buy

      100.00%

    • Hold

      0.00%

    • Sell

      0.00%

    Price Target

    No Data